Piper Sandler lowered the firm’s price target on Pacific Biosciences to $10 from $11 and keeps a Neutral rating on the shares following the recent earnings report.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on PACB:
- PacBio Announces Fourth Quarter and Fiscal Year 2022 Financial Results
- Pacific Biosciences reports Q4 adjusted EPS (35c), consensus (36c)
- Pac Bio options imply 4.4% move in share price post-earnings
- Pacific Biosciences initiated with a Neutral at UBS
- Pacific Biosciences 17.5M share Spot Secondary priced at $10.00
